{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:44:48Z","timestamp":1794854688220,"version":"4.9.1"},"reference-count":53,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Following the discovery of the JAK2V617F mutation in myeloproliferative neoplasms in 2005, fedratinib was developed as a small molecular inhibitor of JAK2. It was optimized to yield low-nanomolar activity against JAK2 (50% inhibitory concentration = 3 nM) and was identified to be selective for JAK2 relative to other JAK family members (eg, JAK1, JAK3, and TYK2). It quickly moved into clinical development with a phase 1 clinical trial opening in 2008, where a favorable impact on spleen and myelofibrosis (MF) symptom responses was reported. A phase 3 trial in JAK2 inhibitor treatment-naive MF patients followed in 2011 (JAKARTA); a phase 2 trial in MF patients resistant or intolerant to ruxolitinib followed in 2012 (JAKARTA-2). Clinical development suffered a major setback between 2013 and 2017 when the US Food and Drug Administration (FDA) placed fedratinib on clinical hold due to the development of symptoms concerning for Wernicke encephalopathy (WE) in 8 of 608 subjects (1.3%) who had received the drug. It was ultimately concluded that there was no evidence that fedratinib directly induces WE, but clear risk factors (eg, poor nutrition, uncontrolled gastrointestinal toxicity) were identified. In August 2019, the FDA approved fedratinib for the treatment of adults with intermediate-2 or high-risk MF. Notably, approval includes a \u201cblack box warning\u201d on the risk of serious and fatal encephalopathy, including WE. FDA approval was granted on the basis of the JAKARTA studies in which the primary end points (ie, spleen and MF symptom responses) were met in \u223c35% to 40% of patients (JAKARTA) and 25% to 30% of patients (JAKARTA-2), respectively.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000954","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T11:39:42Z","timestamp":1588073982000},"page":"1792-1800","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":90,"title":["Fedratinib in myelofibrosis"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9727-8495","authenticated-orcid":false,"given":"Ann","family":"Mullally","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Brigham and Women\u2019s Hospital, and"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"},{"name":"Broad Institute, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hood","sequence":"additional","affiliation":[{"name":"Endeavor Biomedicines, San Diego, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[{"name":"Guy\u2019s and St. Thomas\u2019 NHS Foundation Trust, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-7972","authenticated-orcid":false,"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"Mays Cancer Center, UT Health San Antonio MD Anderson, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,4,28]]},"reference":[{"issue":"4","key":"2020072310460999300_B1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"17","key":"2020072310460999300_B2","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"7037","key":"2020072310460999300_B3","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"9464","key":"2020072310460999300_B4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"2020072310460999300_B5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/asheducation-2014.1.268","article-title":"How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?","volume":"2014","author":"Chen","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"2020072310460999300_B6","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2016-10-696005","article-title":"Myeloproliferative neoplasm stem cells","volume":"129","author":"Mead","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2020072310460999300_B7","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"2020072310460999300_B8","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood-2005-02-0707","article-title":"Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog","volume":"106","author":"Boggon","year":"2005","journal-title":"Blood"},{"issue":"8","key":"2020072310460999300_B9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design","volume":"6","author":"Waldmann","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2020072310460999300_B10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera","volume":"13","author":"Wernig","year":"2008","journal-title":"Cancer Cell"},{"issue":"4","key":"2020072310460999300_B11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"issue":"10","key":"2020072310460999300_B12","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"2020072310460999300_B13","doi-asserted-by":"crossref","first-page":"283617","DOI":"10.1155\/2014\/283617","article-title":"JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis","volume":"2014","author":"Hsu","year":"2014","journal-title":"J Immunol Res"},{"issue":"5-6","key":"2020072310460999300_B14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1759720X18776224","article-title":"The role of the JAK\/STAT signal pathway in rheumatoid arthritis [published correction appears in Ther Adv Musculoskelet Dis. 2018;10(11):225]","volume":"10","author":"Malemud","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2020072310460999300_B15","first-page":"89","article-title":"Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes","volume":"7","author":"Mughal","year":"2014","journal-title":"Int J Gen Med"},{"issue":"15","key":"2020072310460999300_B16","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2020072310460999300_B17","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1038\/bcj.2011.43","article-title":"Pacritinib (SB1518), a JAK2\/FLT3 inhibitor for the treatment of acute myeloid leukemia","volume":"1","author":"Hart","year":"2011","journal-title":"Blood Cancer J"},{"issue":"25","key":"2020072310460999300_B18","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1182\/blood-2009-05-223727","article-title":"CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms","volume":"115","author":"Tyner","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2020072310460999300_B19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ccr.2008.02.017","article-title":"Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors","volume":"13","author":"Geron","year":"2008","journal-title":"Cancer Cell"},{"issue":"9","key":"2020072310460999300_B20","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1038\/leu.2008.56","article-title":"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients","volume":"22","author":"Lasho","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"2020072310460999300_B21","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"issue":"7","key":"2020072310460999300_B22","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020072310460999300_B23","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"issue":"7","key":"2020072310460999300_B24","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"issue":"15","key":"2020072310460999300_B25","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s40265-019-01205-x","article-title":"Fedratinib: first approval","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"issue":"4","key":"2020072310460999300_B26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/jcph.218","article-title":"A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers","volume":"54","author":"Zhang","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"2020072310460999300_B27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/asheducation-2017.1.489","article-title":"Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond","volume":"2017","author":"Harrison","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"2020072310460999300_B28","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2020072310460999300_B29","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2020072310460999300_B30","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2020072310460999300_B31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann Hematol"},{"key":"2020072310460999300_B32","doi-asserted-by":"crossref","first-page":"S356","DOI":"10.1016\/j.clml.2019.07.375","article-title":"Fedratinib induces spleen responses in patients with myeloproliferative neoplasm (MPN)-associated intermediate- or high-risk myelofibrosis (MF) resistant or intolerant to ruxolitinib: an updated analysis of the phase II JAKARTA2 study [abstract]","volume":"19","author":"Harrison","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2020072310460999300_B33","first-page":"Abstract 4197","article-title":"Case series of potential Wernicke\u2019s encephalopathy in patients treated with fedratinib [abstract]","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2020072310460999300_B34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/bjh.14128","article-title":"Thiamine deficiency appears uncommon in patients with myeloproliferative neoplasms","volume":"178","author":"Curto-Garc\u00eda","year":"2017","journal-title":"Br J Haematol"},{"issue":"2","key":"2020072310460999300_B35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41408-018-0167-3","article-title":"A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy","volume":"9","author":"Gangat","year":"2019","journal-title":"Blood Cancer J"},{"issue":"11","key":"2020072310460999300_B36","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/j.clml.2018.06.025","article-title":"Ruxolitinib rechallenge can improve constitutional symptoms and splenomegaly in patients with myelofibrosis: a case series","volume":"18","author":"Gerds","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"2020072310460999300_B37","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","article-title":"NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018","volume":"15","author":"Mesa","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"2020072310460999300_B38","doi-asserted-by":"crossref","first-page":"Abstract 668","DOI":"10.1182\/blood-2019-129288","article-title":"Fedratinib induces spleen responses and reduces symptom burden in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) and low platelet counts, who were either ruxolitinib-naive or were previously treated with ruxolitinib [abstract]","volume":"134","author":"Harrison","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2020072310460999300_B39","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"issue":"5","key":"2020072310460999300_B40","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"key":"2020072310460999300_B41","doi-asserted-by":"crossref","first-page":"Abstract 4175","DOI":"10.1182\/blood-2019-129245","article-title":"Pacifica: a randomized, controlled phase 3 study of pacritinib vs. physician\u2019s choice in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or post essential thrombocytopenia myelofibrosis with severe thrombocytopenia (platelet count &lt;50,000\/mL) [abstract]","volume":"134","author":"Harrison","year":"2019","journal-title":"Blood"},{"issue":"34","key":"2020072310460999300_B42","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020072310460999300_B43","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"issue":"2","key":"2020072310460999300_B44","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/leu.2016.215","article-title":"A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis","volume":"31","author":"Verstovsek","year":"2017","journal-title":"Leukemia"},{"key":"2020072310460999300_B45","doi-asserted-by":"crossref","first-page":"Abstract 557","DOI":"10.1182\/blood-2019-122546","article-title":"A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia [abstract]","volume":"134","author":"Gerds","year":"2019","journal-title":"Blood"},{"key":"2020072310460999300_B46","doi-asserted-by":"crossref","first-page":"Abstract 670","DOI":"10.1182\/blood-2019-127119","article-title":"MANIFEST, a phase 2 study of CPI-0610, a bromodomain and extraterminal domain inhibitor (BETi), as monotherapy or \u201cadd-on\u201d to ruxolitinib, in patients with refractory or intolerant advanced myelofibrosis [abstract]","volume":"134","author":"Mascarenhas","year":"2019","journal-title":"Blood"},{"key":"2020072310460999300_B47","doi-asserted-by":"crossref","first-page":"Abstract 671","DOI":"10.1182\/blood-2019-130158","article-title":"Results from a phase 2 study of navitoclax in combination with ruxolitinib in patients with primary or secondary myelofibrosis [abstract]","volume":"134","author":"Harrison","year":"2019","journal-title":"Blood"},{"key":"2020072310460999300_B48","doi-asserted-by":"crossref","first-page":"Abstract 672","DOI":"10.1182\/blood-2019-127859","article-title":"Updated results from the German Mpnsg-0212 combination trial: ruxolitinib plus pomalidomide in myelofibrosis with anemia [abstract]","volume":"134","author":"Stegelmann","year":"2019","journal-title":"Blood"},{"key":"2020072310460999300_B49","doi-asserted-by":"crossref","first-page":"Abstract 4163","DOI":"10.1182\/blood-2019-127661","article-title":"Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: a phase II study [abstract]","volume":"134","author":"Rampal","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2020072310460999300_B50","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N Engl J Med"},{"key":"2020072310460999300_B51","doi-asserted-by":"crossref","first-page":"Abstract 556","DOI":"10.1182\/blood-2019-123244","article-title":"A phase 2a study of the LSD1 inhibitor Img-7289 (bomedemstat) for the treatment of myelofibrosis [abstract]","volume":"134","author":"Pettit","year":"2019","journal-title":"Blood"},{"key":"2020072310460999300_B52","doi-asserted-by":"crossref","first-page":"Abstract 555","DOI":"10.1182\/blood-2019-130046","article-title":"Final results of phase 2 clinical trial of LCL161, a novel oral SMAC mimetic\/IAP antagonist, for patients with intermediate to high risk myelofibrosis [abstract]","volume":"134","author":"Pemmaraju","year":"2019","journal-title":"Blood"},{"key":"2020072310460999300_B53","doi-asserted-by":"crossref","first-page":"Abstract 558","DOI":"10.1182\/blood-2019-131217","article-title":"Results from a phase 1\/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate, or high risk, relapsed\/refractory myelofibrosis [abstract]","volume":"134","author":"Pemmaraju","year":"2019","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2020002897","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/8\/1792\/1749506\/advancesadv2019000954c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/8\/1792\/1749506\/advancesadv2019000954c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T10:46:53Z","timestamp":1595501213000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/8\/1792\/454549\/Fedratinib-in-myelofibrosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,28]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,4,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000954","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,28]]}}}